Insights into Managing Non-Hodgkin B-Cell Lymphoma Edition
This edition of the Living Medical eTextbook contains comprehensive peer-reviewed medical information, approved guidelines, and treatment strategies. There are links to external resources that help clarify relevant issues and enhance learning. The book is curated and edited by noted thought leaders. Free CME/CE credit is offered.
In chapter 1, Pathophysiology, Diagnosis and Calssifcation of B-Cell Non-Hodgkin Lymphoma: Implications for Personalized Prognosis and Treatment, Stephanie A. Gregory, MD, describes epidemiology, risk factors, diagnostic and work-up methodology, current status of subtype classification and disease prognostication, and the role of gene expression profiling.
In Chapter 2, Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma–Current Practice and Unmet Needs, John P. Leonard, MD, reviews current treatment options for indolent and aggressive B-cell lymphoma, focusing on follicular lymphoma and diffuse large B-cell lymphoma. Discussion includes options for newly diagnosed as well as relapsed or refractory disease, factors to consider when individualizing treatment, and novel therapies on the horizon.
Treatment regimens incorporating rituximab are the standard of care for patients with B-cell Non-Hodgkin Lymphoma, and several other monoclonal antibodies to CD20 and to other antigens are in development. In Chapter 3, Monoclonal Antibodies in B-Cell Non-Hodgkin Lymphoma: Past, Present, and Future, Myron S. Czuczman, MD, reviews the benefits, limitations, and unmet needs of patients receiving rituximab-based therapy for B-cell Non-Hodgkin Lymphoma and describes investigational monoclonal antibodies for B-cell Non-Hodgkin Lymphoma.